High Growth Tech Stocks in the US to Watch This May 2025
The U.S. stock market has experienced significant volatility recently, with major indices like the Dow Jones and Nasdaq Composite seeing sharp gains following a tech sector rally driven by shifts in trade policy under the Trump administration. In this dynamic environment, high-growth tech stocks can be particularly appealing to investors seeking opportunities that align with current market momentum and technological advancements.
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Mereo BioPharma Group | 53.63% | 66.57% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
★★★★★☆
aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation by leveraging tRNA synthetase biology, with a market cap of $333.77 million.
Focused on the discovery and development of innovative therapies, aTyr Pharma leverages tRNA synthetase biology to address fibrosis and inflammation.
aTyr Pharma, despite being unprofitable, is positioned for significant growth with a forecasted revenue increase of 62.4% per year, outpacing the US market's average of 8.6%. This biotech firm is expected to turn profitable within the next three years, supported by a robust earnings growth projection of 65.65% annually. Recent advancements include progressing their investigational drug ATYR0101 and appointing Dalia R. Rayes as Head of Commercial for their efzofitimod program, signaling strategic moves to enhance their commercial capabilities in addressing interstitial lung diseases.
★★★★☆☆
Simulations Plus, Inc. specializes in creating software for drug discovery and development that leverages artificial intelligence and machine learning to model and predict molecular properties, with a market cap of $664.57 million.
Operations: The company generates revenue primarily through its software segment, which accounts for $46.02 million, and services segment contributing $32.54 million. The business leverages advanced technologies like AI and machine learning in the pharmaceutical industry to enhance drug discovery and development processes.
